Catheter-Related Bloodstream Infection Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Catheter-Related Bloodstream Infection Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

“Catheter-Related Bloodstream Infection Market”
DelveInsight’s “Catheter-Related Bloodstream Infection (CRBSI) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Catheter-Related Bloodstream Infection (CRBSI), historical and forecasted epidemiology as well as the Catheter-Related Bloodstream Infection (CRBSI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Catheter-Related Bloodstream Infection (CRBSI) Market Insights, Epidemiology, and Market Forecast-2032  report delivers an in-depth understanding of the Catheter-Related Bloodstream Infection (CRBSI), historical and forecasted epidemiology as well as the Catheter-Related Bloodstream Infection (CRBSI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Catheter-Related Bloodstream Infection (CRBSI) market report provides current treatment practices, emerging drugs, Catheter-Related Bloodstream Infection (CRBSI) market share of the individual therapies, current and forecasted Catheter-Related Bloodstream Infection (CRBSI) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Catheter-Related Bloodstream Infection (CRBSI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Catheter-Related Bloodstream Infection (CRBSI) market.

Some of the key benefits of the “Catheter-Related Bloodstream Infection  Market Report:

  • The report covers the descriptive overview of Catheter-Related Bloodstream Infection (CRBSI), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Catheter-Related Bloodstream Infection (CRBSI) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Catheter-Related Bloodstream Infection (CRBSI) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Catheter-Related Bloodstream Infection (CRBSI) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Catheter-Related Bloodstream Infection (CRBSI) market

Got queries? Click here to know more about the Catheter-Related Bloodstream Infection  Market Landscape 

Catheter-Related Bloodstream Infection  Overview

Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravenous catheter. It is one of the most frequent, lethal, and costly complications of central venous catheterization and also the most common cause of nosocomial bacteremia.

Potential risk factors for catheter-related bloodstream infection (CRBSI) include underlying disease, method of catheter insertion, and duration and purpose of catheterization. The administration of parenteral nutrition (PN) through intravascular catheters increases CRBSI risks.

Signs and symptoms include fevers and chills or the skin around the catheter may become sore and red.

Catheter-Related Bloodstream Infection  Epidemiological Insights:

  • Despite high incidence rates, little information is available on the burden of illness of catheter-related bloodstream infections (CRBSIs) in Europe. A review of the available data was performed to estimate the clinical outcomes and costs associated with CRBSIs during intensive care unit (ICU) stays in four European countries (France, Germany, Italy and the UK). Based on these data we have estimated the CRBSI-related mortality and the annual costs associated with CRBSIs in the aforementioned countries. Results show large variation between countries: 1.12-4.2 CRBSI per 1000 catheter days, 8400-14,400 CRBSIs episodes per year, 1000-1584 deaths per year, 15,960-201,600 ICU days caused by CRBSIs and euro35.9 to euro163.9 million associated costs. Discrepancies are mainly explained by the heterogeneous quality of epidemiological studies, as well as the variety of national clinical practices
  • In 2017, there were 24,265 central line-associated bloodstream infections (CLABSIs) reported by 3576 United States acute care hospitals to the United States Centers for Disease Control and Prevention’s National Healthcare Safety Network. This represents a 19 percent decline compared with the 2015 

Catheter-Related Bloodstream Infection  Market Epidemiological Segmentation

  • Catheter-Related Bloodstream Infection total prevalent population
  • Catheter-Related Bloodstream Infection total age-specific diagnosed cases
  • Catheter-Related Bloodstream Infection total gender-specific diagnosed cases
  • Catheter-Related Bloodstream Infection total treated cases

Catheter-Related Bloodstream Infection  Market Market Outlook 

The Catheter-Related Bloodstream Infection (CRBSI) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Catheter-Related Bloodstream Infection (CRBSI) market trends by analyzing the impact of current Catheter-Related Bloodstream Infection (CRBSI) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Catheter-Related Bloodstream Infection (CRBSI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Catheter-Related Bloodstream Infection (CRBSI) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Catheter-Related Bloodstream Infection (CRBSI) market in 7MM is expected to witness a major change in the study period 2019-2032.

  

Learn more by requesting for sample @Catheter-Related Bloodstream Infection  Market Landscape

Catheter-Related Bloodstream Infection Market Key Companies  

  • Eisai/BioArctic
  • Biogen 
  • Hoffmann-La Roche
  • Cortexyme Pharmaceutical
  • And many more

Catheter-Related Bloodstream Infection Market Therapies 

  • Lecanemab (BAN2401) 
  • Aducanumab (BIIB037)
  • Gantenerumab
  • Atuzaginstat (COR388)
  • And many more

Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of “Catheter-Related Bloodstream Infection  Market 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Catheter-Related Bloodstream Infection  Market   Emerging Therapies
  • Catheter-Related Bloodstream Infection  Market  Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  • Catheter-Related Bloodstream Infection  Market  Report Methodology
  • DelveInsight Capabilities
  • Disclaimer
  • About DelveInsight

Click here to read more about Catheter-Related Bloodstream Infection  Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/